CTOs on the Move

Pliant Therapeutics

www.pliantrx.com

 
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. Pliant`s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.pliantrx.com
  • 260 Littlefield Avenue
    South San Francisco, CA USA 94080
  • Phone: 650.481.6770

Executives

Name Title Contact Details
Tim Saunders
Head Of Information Technology Profile
Diane Ireland
Head of Facilities, IT and Operations Profile

Funding

Pliant Therapeutics raised $62M on 07/16/2018
Pliant Therapeutics raised $100M on 03/03/2020

Similar Companies

MOLLI Surgical

#Healthcare needs to get simpler to get better. To achieve this, we focus on the #patientexperience and develop more effective #medicaldevices. #breastcancer

EQRx

EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines.

Teligent

Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Called TICO, our strategy is focused on developing and selling pharmaceutical products in the Topical, Injectable, Complex and Ophthalmic markets. Based in Buena, New Jersey, we have approximately 200 employees working at our 33,000 square-foot manufacturing and R&D complex, as well as in our Canada and Estonia operations. We are currently expanding our New Jersey site to include a sterile injectable, isolator-based manufacturing suite and an expanded footprint for the production of our topical products. There are three pillars that shape our company. First, we are driven by impactful science. Second, we accept no middle ground when it comes to product quality. Finally, we believe in fostering a career of craftsmanship, where our people can become experts in their trade. The spirit of our culture is to work hard, and be nice to people.

Ionetix

Ionetix Corporation is a pioneering radiopharmaceutical end to end solutions provider for cardiac PET. Cardiac PET with Ammonia N-13.